|Bid||54.57 x 900|
|Ask||54.85 x 1100|
|Day's range||54.13 - 58.63|
|52-week range||6.70 - 146.16|
|Beta (5Y monthly)||0.51|
|PE ratio (TTM)||N/A|
|Earnings date||10 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||13 Dec 2012|
|1y target est||159.25|
Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.
Biogen's (BIIB) regulatory application seeking approval for its Alzheimer's drug, Aduhelm, in Europe hits setback as it receives negative trend vote from the CHMP.
Second Phase 3 Study is Designed to Evaluate Safety and Efficacy of Simufilam Over 78 Weeks in 1,000 Patients with Alzheimer’s DiseaseAUSTIN, Texas, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, announced today it has initiated a second Phase 3 study of simufilam, the Company’s investigational drug for patients with Alzheimer’s disease. This second Phase 3 study is designed to evaluate the safety and efficacy of simufilam over 78 weeks in appro